Qlaris Bio Announces Development of Fixed-Dose Combination Therapy with QLS‑111 and Latanoprost for the Treatment of Glaucoma

Combination therapy seeks to improve intraocular pressure lowering by pairing a novel EVP-targeting agent with prostaglandin analogue standard of care

Excerpt from the Press Release:

DEDHAM, Mass.–(BUSINESS WIRE)–Qlaris Bio, Inc., a clinical-stage biotechnology company, today announced that it is developing a novel preservative-free, fixed-dose combination (FDC) therapy that combines the company’s lead program, QLS-111, and latanoprost, the most commonly prescribed prostaglandin analogue for the treatment of glaucoma. The QLS-111 and latanoprost fixed-dose combination (QLS-111-FDC) is being developed as a treatment for patients with primary open angle glaucoma (POAG), ocular hypertension (OHT), and normal tension glaucoma (NTG) for whom optimal intraocular pressure (IOP) control may remain unachievable due to the need to lower episcleral venous pressure (EVP). EVP, which is the target of QLS-111, remains the only component of IOP that is not addressed by currently approved treatments.

QLS-111 utilizes a first-in-class ATP-sensitive potassium channel modulator designed to lower IOP by selectively reducing EVP, which may represent the largest component of IOP in patients. Latanoprost, a gold standard in glaucoma care, lowers IOP by increasing uveoscleral outflow. Together, the agents offer a complementary dual mechanism approach aimed to further enhance IOP control. Reduction of IOP remains the only modifiable risk factor shown to slow the progression to blindness in patients with glaucoma.

Click the button below to read the entire Press Release:

Continue Reading The Press Release